Literature DB >> 23962238

Rift Valley fever virus structural and nonstructural proteins: recombinant protein expression and immunoreactivity against antisera from sheep.

Bonto Faburay1, William Wilson, D Scott McVey, Barbara S Drolet, Hana Weingartl, Daniel Madden, Alan Young, Wenjun Ma, Juergen A Richt.   

Abstract

The Rift Valley fever virus (RVFV) encodes the structural proteins nucleoprotein (N), aminoterminal glycoprotein (Gn), carboxyterminal glycoprotein (Gc), and L protein, 78-kD, and the nonstructural proteins NSm and NSs. Using the baculovirus system, we expressed the full-length coding sequence of N, NSs, NSm, Gc, and the ectodomain of the coding sequence of the Gn glycoprotein derived from the virulent strain of RVFV ZH548. Western blot analysis using anti-His antibodies and monoclonal antibodies against Gn and N confirmed expression of the recombinant proteins, and in vitro biochemical analysis showed that the two glycoproteins, Gn and Gc, were expressed in glycosylated form. Immunoreactivity profiles of the recombinant proteins in western blot and in indirect enzyme-linked immunosorbent assay against a panel of antisera obtained from vaccinated or wild type (RVFV)-challenged sheep confirmed the results obtained with anti-His antibodies and demonstrated the suitability of the baculo-expressed antigens for diagnostic assays. In addition, these recombinant proteins could be valuable for the development of diagnostic methods that differentiate infected from vaccinated animals (DIVA).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23962238      PMCID: PMC3777644          DOI: 10.1089/vbz.2012.1285

Source DB:  PubMed          Journal:  Vector Borne Zoonotic Dis        ISSN: 1530-3667            Impact factor:   2.133


  64 in total

1.  Characterization of the Golgi retention motif of Rift Valley fever virus G(N) glycoprotein.

Authors:  Sonja R Gerrard; Stuart T Nichol
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR(-/-) mice induced by different DNA vaccination regimens.

Authors:  Gema Lorenzo; Raquel Martín-Folgar; Esther Hevia; Hani Boshra; Alejandro Brun
Journal:  Vaccine       Date:  2010-02-25       Impact factor: 3.641

3.  Potential for North American mosquitoes (Diptera: Culicidae) to transmit rift valley fever virus.

Authors:  Michael J Turell; William C Wilson; Kristine E Bennett
Journal:  J Med Entomol       Date:  2010-09       Impact factor: 2.278

Review 4.  Rift valley fever vaccines.

Authors:  Tetsuro Ikegami; Shinji Makino
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

5.  Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep.

Authors:  Gema Lorenzo; Raquel Martín-Folgar; Fernando Rodríguez; Alejandro Brun
Journal:  Vaccine       Date:  2008-08-03       Impact factor: 3.641

6.  Recombinant nucleocapsid-based ELISA for detection of IgG antibody to Rift Valley fever virus in African buffalo.

Authors:  Janusz T Paweska; Petrus Jansen van Vuren; Alan Kemp; Peter Buss; Roy G Bengis; Francis Gakuya; Robert F Breiman; M Kariuki Njenga; Robert Swanepoel
Journal:  Vet Microbiol       Date:  2007-08-17       Impact factor: 3.293

7.  Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR.

Authors:  Christian Drosten; Stephan Göttig; Stefan Schilling; Marcel Asper; Marcus Panning; Herbert Schmitz; Stephan Günther
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

8.  Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs.

Authors:  Nina Lagerqvist; Jonas Näslund; Ake Lundkvist; Michèle Bouloy; Clas Ahlm; Göran Bucht
Journal:  Virol J       Date:  2009-01-17       Impact factor: 4.099

9.  Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins.

Authors:  Li Liu; Cristina C P Celma; Polly Roy
Journal:  Virol J       Date:  2008-07-18       Impact factor: 4.099

10.  A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells.

Authors:  Nicolas Le May; Zeyni Mansuroglu; Psylvia Léger; Thibaut Josse; Guillaume Blot; Agnès Billecocq; Ramon Flick; Yves Jacob; Eliette Bonnefoy; Michèle Bouloy
Journal:  PLoS Pathog       Date:  2008-01       Impact factor: 6.823

View more
  19 in total

1.  Evaluation of an Indirect Enzyme-Linked Immunosorbent Assay Based on Recombinant Baculovirus-Expressed Rift Valley Fever Virus Nucleoprotein as the Diagnostic Antigen.

Authors:  Bonto Faburay; William C Wilson; Arss Secka; Barbara Drolet; D Scott McVey; Juergen A Richt
Journal:  J Clin Microbiol       Date:  2019-09-24       Impact factor: 5.948

Review 2.  Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.

Authors:  Tetsuro Ikegami
Journal:  Expert Rev Vaccines       Date:  2017-05-02       Impact factor: 5.217

3.  Evaluation of Fluorescence Microsphere Immunoassay for Detection of Antibodies to Rift Valley Fever Virus Nucleocapsid Protein and Glycoproteins.

Authors:  I K Ragan; A S Davis; D S McVey; J A Richt; R R Rowland; W C Wilson
Journal:  J Clin Microbiol       Date:  2018-05-25       Impact factor: 5.948

4.  A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep.

Authors:  Bonto Faburay; Maxim Lebedev; D Scott McVey; William Wilson; Igor Morozov; Alan Young; Juergen A Richt
Journal:  Vector Borne Zoonotic Dis       Date:  2014-10       Impact factor: 2.133

5.  Countermeasure development for Rift Valley fever: deletion, modification or targeting of major virulence factor NSs.

Authors:  Olga Lihoradova; Tetsuro Ikegami
Journal:  Future Virol       Date:  2014-01-01       Impact factor: 1.831

6.  The use of Nanotrap particles in the enhanced detection of Rift Valley fever virus nucleoprotein.

Authors:  Nazly Shafagati; Lindsay Lundberg; Alan Baer; Alexis Patanarut; Katherine Fite; Benjamin Lepene; Kylene Kehn-Hall
Journal:  PLoS One       Date:  2015-05-28       Impact factor: 3.240

7.  Rift Valley fever virus incorporates the 78 kDa glycoprotein into virions matured in mosquito C6/36 cells.

Authors:  Hana M Weingartl; Shunzhen Zhang; Peter Marszal; Alan McGreevy; Lynn Burton; William C Wilson
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

8.  Experimental Infection of Calves by Two Genetically-Distinct Strains of Rift Valley Fever Virus.

Authors:  William C Wilson; A Sally Davis; Natasha N Gaudreault; Bonto Faburay; Jessie D Trujillo; Vinay Shivanna; Sun Young Sunwoo; Aaron Balogh; Abaineh Endalew; Wenjun Ma; Barbara S Drolet; Mark G Ruder; Igor Morozov; D Scott McVey; Juergen A Richt
Journal:  Viruses       Date:  2016-05-23       Impact factor: 5.048

9.  A Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Confers Full Protection against Rift Valley Fever Challenge in Sheep.

Authors:  Bonto Faburay; William C Wilson; Natasha N Gaudreault; A Sally Davis; Vinay Shivanna; Bhupinder Bawa; Sun Young Sunwoo; Wenjun Ma; Barbara S Drolet; Igor Morozov; D Scott McVey; Juergen A Richt
Journal:  Sci Rep       Date:  2016-06-14       Impact factor: 4.379

10.  Preliminary Evaluation of a Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Providing Full Protection against Heterologous Virulent Challenge in Cattle.

Authors:  William C Wilson; Bonto Faburay; Jessie D Trujillo; Izabela Ragan; Sun-Young Sunwoo; Igor Morozov; Vinay Shivanna; Aaron Balogh; Kinga Urbaniak; D Scott McVey; Dashzeveg Bold; Natasha N Gaudreault; Erin E Schirtzinger; Wenjun Ma; Juergen A Richt
Journal:  Vaccines (Basel)       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.